Evidence map›Paper›PMID 38137433›Full record

ArticleBiomedicines2023

siRNA-Mediated B7H7 Knockdown in Gastric Cancer Lysate-Loaded Dendritic Cells Amplifies Expansion and Cytokine Secretion of Autologous T Cells.

Javad Masoumi, Farid Ghorbaninezhad, Hossein Saeedi, Sahar Safaei, Vahid Khaze Shahgoli, Amir Ghaffari Jolfayi, Bahar Naseri, Amir Baghbanzadeh, Elham Baghbani, Ahad Mokhtarzadeh and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Oncology letters · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Javad MasoumiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Farid GhorbaninezhadImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.ORCID 0000-0002-0175-204X
Hossein SaeediImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.ORCID 0000-0001-6413-3214
Sahar SafaeiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Vahid Khaze ShahgoliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Amir Ghaffari JolfayiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.ORCID 0000-0002-9223-5565
Bahar NaseriImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Amir BaghbanzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Elham BaghbaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.ORCID 0000-0002-7529-108X
Ahad MokhtarzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Mohammad BakhshivandImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.
Mohammad Reza JavanDepartment of Immunology, Faculty of Medicine, Zabol University of Medical Sciences, Zabol 98616-15881, Iran.
Nicola SilvestrisMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 51548-53431, Iran.ORCID 0000-0002-8642-6795
Tabriz University of Medical Sciences · IRUniversity of Messina · ITZabol University of Medical Sciences · IR

Funding

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 67525
6 · The paper itself

Abstract

backgroundGastric cancer, ranked as the fifth most common cancer worldwide, presents multiple treatment challenges. These obstacles often arise due to cancer stem cells, which are associated with recurrence, metastasis, and drug resistance. While dendritic cell (DC)-based immunotherapy has shown promise as a therapeutic strategy, its efficacy can be limited by the tumor microenvironment and certain inhibitory immune checkpoint molecules, such as B7H7. SiRNA-medicated knockdown of B7H7 in tumor cell lysate-pulsed DCs can increase cytokine secretion and autologous T lymphocyte expansion. This study aimed to evaluate the impact of B7H7 suppression in gastric cancer cell lysate-pulsed DCs on the stimulatory potential of autologous CD3

methodsPeripheral blood mononuclear cells (PBMCs) were isolated and monocytes were obtained; then, they were differentiated to immature DCs (iDCs) by GM-CSF and IL-4. Tumor cell lysates from human gastric cancer cell lines were harvested, and iDCs were transformed into mature DCs (mDCs) by stimulating iDCs with tumor cell lysate and lipopolysaccharide. B7H7-siRNA was delivered into mDCs using electroporation, and gene silencing efficiency was assessed. The phenotypic characteristics of iDCs, mDCs, and B7H7-silenced mDCs were evaluated using specific surface markers, an inverted light microscope, and flow cytometry. CD3

resultsTransfection of B7H7 siRNA into mDCs was performed in optimal conditions, and the siRNA transfection effectively reduced B7H7 mRNA expression in a dose-dependent manner. SiRNA-mediated B7H7 knockdown in mDCs enhanced maturation and activation of the DCs, as demonstrated by an increased surface expression of CD11c, CD86, and CD40. Co-culture experiments revealed that B7H7-silenced mDCs had more capacity to induce T cell proliferation compared to non-transfected mDCs. The cytokine production patterns of T cells were also altered. Upon examining the levels of TGF-β, IL-4, and IFN-γ released by CD3

conclusionsThe study found that suppressing B7H7 expression in DCs significantly enhances their maturation and stimulatory activity when exposed to gastric cancer cell lysate. These B7H7-silenced DCs can substantially increase cytokine production and promote co-cultured T-cell expansion. Consequently, inhibiting B7H7 in DCs may offer a practical strategy to enhance the ability of DCs to initiate T lymphocyte responses and improve the effectiveness of DC-based cell therapy for cancer patients.

Indexed as

B7H7DC-based cell therapydendritic cellgastric cancerT cell

Identifiers

PMID38137433
PMCPMC10740599
OpenAlexW4389310735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.